Cardiovascular
| ETC-216 - Phospholipid | ||
ETC-216 is a synthetic variant of high-density lipoprotein (HDL) and one of several HDL targeted therapies the company is developing for patients with CHD. |
Contrast between a healthy and an atherosclerotic artery. (Source: ABPI) |
Single agent therapy. (Source: ABPI) |
| Exanta - Oral Direct Thrombin Inhibitor for the | ||
Exanta (ximelagatran) is an oral direct thrombin inhibitor developed by AstraZeneca. It is indicated for the prevention and treatment of venous thromboembolism (VTE) and potentially for the prevention of stroke in patients with atrial fibrillation. (Source: ABPI) |
VTE encompasses both DVT and PE and is the third most common cardiovascular disease after heart attack and stroke. |
Drawbacks associated with the routine use of Warfarin for anti-coagulation therapy. |
| Idraparinux - Investigational Agent for the, | ||
VTE is the third most common cardiovascular disease after heart attack and stroke. (Source: ABPI) |
Rick factors for DVT. |
Idraparinux is a new addition to the synthetic oligosaccharide family of anticoagulant drugs. |
PERSIST, a phase II dose-ranging study was completed in 2002. |
PERSIST results showed that at a dose of 2.5mg idraparinux was at least as effective as existing treatments in VTE prevention. |
|
| Istaroxime, | ||
Diagram of the heart showing the major arteries, veins, valves and the direction of blood flow. Deoxygenated blood is shown in purple and oxygenated blood in red. |
Summary of major and minor diagnostic criteria for CHF derived from the Framingham Heart Study. |
CHF is a progressive disease, which if left untreated leads inexorably to acute heart failure and potentially death. |
Triggering a heartbeat. Calcium floods into heart cells through the calcium channel at each beat, which releases internal stored calcium (blue arrows). This causes the muscle to contract. Three calcium channel blockers act at different sites in this calci |
||
| Lipitor / Torcetrapib - Combination Therapy | ||
A lack of oxygen supply to the heart leads to adverse clinical consequences such as angina, heart attack (myocardial infarction) and sudden cardiac death. |
Atheroclerosis is a pathological process in which arteries supplying the heart become progressively narrowed by the build up of fatty material in the artery wall. (Source: ABPI) |
Pfizer is exploring the potential to combine its top selling statin Lipitor (atorvastatin) with its investigational compound CP-529,414 for the treatment of dyslipidaemia. |
| Multaq | ||
Dronedarone is a new Class III antiarrhythmic drug under development by Sanofi-Aventis. |
Sanofi-Aventis' Ambarès manufacturing facility. |
A granulation operator at Sanofi-Aventis' Ambarès manufacturing facility. |
Capsule production line at Sanofi-Aventis' Ambarès manufacturing facility. |
Monitoring substance dissolution at Sanofi-Aventis' Ambarès manufacturing facility. |
Monitoring tablet production at Sanofi-Aventis' Ambarès manufacturing facility. |
Vials of tablets produced at Sanofi-Aventis' Ambarès manufacturing facility. |
||
| Pradaxa – Oral Direct Thrombin Inhibitor | ||
Cross-section of the human heart. |
Venous thromboembolism (VTE) is the process in which a blood clot, or thrombus, forms in the vein. It can lead to deep vein thrombosis (DVT) and pulmonary embolism (PE). |
Several factors can predispose people to increased risk of developing DVT or PE. |
In clinical use for some 50 years, the vitamin K antagonist warfarin remains the standard long-term oral anticoagulant. However, warfarin has a number of significant drawbacks driving the search for safer and more effective oral anticoagulants. |
Pradaxa (dabigatran etexilate) is a new oral anticoagulant under development by Boehringer Ingelheim. |
|
| Prasugrel - Investigational Antiplatelet Agent | ||
Diagram of the heart. |
A section of an artery showing the formation of an atherosclerotic plaque. |
Diagrammatic representation of clot formation showing platelets and fibrinogen strands. |
The results of the phase III trial showed that treatment with prasugrel was associated with a significant reduction in the composite primary efficacy endpoint as well as in MI, urgent target vessel revascularisation (TVR), and stent thrombosis. |
The results of the phase III trial showed that treatment with prasugrel was associated with a significantly increased risk of bleeding. |
|
| Rasilez | ||
Many patients have overlapping risk factors. Among the hypertension population, about two-thirds have dyslipidaemia, while almost half are overweight and a fifth have type 2 diabetes. |
The Renin Angiotensin system (RAS) is one of the key regulators of blood pressure, in which the enzyme renin plays a pivotal role. |
Patients with hypertension often need more than one drug to bring blood pressure to within target levels. Rasilez has demonstrated potent blood-pressure lowering effects. |
Data from the US show that a significant proportion of people with hypertension remain undiagnosed, untreated or diagnosed but not treated. |
||
| TRA-SCH-530348 | ||
Cross-section of the human heart. |
Cross-section of a healthy and diseased artery. |
A section of an artery showing the formation of an atherosclerotic plaque. |
Diagrammatic representation of clot formation showing platelets and fibrinogen strands. |
Common diseases of the heart. |
Antiplatelet drugs such as aspirin and clopidogrel are an important component of secondary prevention of ACS. |
| Xarelto, | ||
Cross-section of the human heart. |
Xarelto (rivaroxaban) targets Factor Xa in the coagulation cascade. |
|
